Check out what our president, Neil Weisman, shares about the FDA's Sudden policy shift on Diversity Action Plans. Continuum Clinical, A Spectrum Science Company #PharmaDEIPledge #Dowhatsright
In a sudden and unexpected move, the FDA has ceased providing access to Diversity Action Plans on their website. This is a wake-up call for ALL OF US in the clinical trial industry. For years, we’ve worked tirelessly to progress and prioritize diversity in clinical trials to ensure that new treatment options are effective for all patients, regardless of race, ethnicity, gender, or age. And just when it felt like we were finally starting to make progress, with a "thanos-like" snap of the fingers, policy has shifted, and the responsibility of maintaining and advancing these efforts now falls squarely on our shoulders. Let’s be clear: we cannot let the rug be pulled out from under us. Progress in clinical trial diversity is not just a regulatory box to check; it’s a moral imperative and a scientific necessity. The well-being of millions depend on our commitment to inclusive research practices. So now, It’s up to us to make sure this change does not derail the strides we’ve made. Our industry has the tools, knowledge, and dedication to carry this mission forward—with or without regulatory support. We cannot let policy police progress. Now is the time to double down on our efforts, to collaborate, and to hold ourselves accountable to the highest standards of DEI in clinical research. This moment is a test of our resolve. So here is my ask to everyone in our industry: Let’s rise to the challenge and ensure that diversity in clinical trials remains a top priority—because when we succeed, patients everywhere benefit. Let’s see this through. Together. Continuum Clinical, A Spectrum Science Company Spectrum Science #PharmaDEIPledge #Dowhatsright